Keita Mori, MBA,
SanBio Co., Ltd. President
SanBio, Inc. Co-CEO, Chairman
Mr. Mori has been Co-Chief Executive Officer and has served as a member of the Board since SanBio's inception in 2001. Prior to founding SanBio, Mr. Mori was Head of New Product Development from 2000 to 2001 at Xuma, an informatics startup in San Francisco. From 1993 to 1999, Mr. Mori held positions of increasing responsibility in R&D and Manufacturing at Kirin Holdings, Ltd. in Japan. Mr. Mori holds an MBA degree from the University of California, Berkeley and a master's degree in Biochemistry from the University of Tokyo.
SanBio Co., Ltd. Exective Chairman
SanBio, Inc. Co-CEO
Mr. Kawanishi served as SanBio's Chairman of the Board from 2001 to 2005 and has been Co-Chief Executive Officer and a member of the Board since 2005. Prior to founding SanBio, Mr. Kawanishi co-founded CareNet, Inc. (TSE: 2150) and was Executive Vice President from 1996 to 1999. At CareNet, Mr. Kawanishi established eHealthcare in Japan. From 1993 to 1996, Mr. Kawanishi was a management consultant at the Boston Consulting Group. Mr. Kawanishi has a master's degree in Biochemistry from the University of Tokyo.
Damien Bates, MD, PhD, FRACS, MBA,
Chief Medical Officer and Head of Research
Dr. Bates is a board certified reconstructive surgeon who has held senior positions in clinical development and medical affairs at Baxter, Organogenesis, and Allergan. In these roles, Dr. Bates specialized in the surgical applications of regenerative medicine and has the distinction of leading the first and only successful regulatory approval of an allogeneic cell therapy product in the US. Dr. Bates received his medical degree from the University of Sydney, his PhD in Developmental Biology from the University of Melbourne, and his MBA from the Wharton Business School.
Jay Stout , PhD,
Senior Vice President, Manufacturing
Dr. Stout is a distinguished industry veteran with 25 years of experience in biologicals development and commercialization. He previously served as Global Process Team Lead for Enbrel, Amgen's blockbuster anti-TNF product, and as Global Technical Lead for Keytruda (pembrolizumab), Merck's antibody which targets the Programmed Cell Death 1 (PD-1) receptor. Keytruda was awarded Breakthrough status by the FDA and was the first anti-PD-1 therapy approved in the United States. A PhD biochemist, Dr. Stout most recently served as Executive Director of Merck's Center for Biopharmaceutical Manufacturing, and previously was Executive Director of Amgen's Manufacturing Sciences and Technology Group. Earlier in his career he started and directed Pfizer's Biologics Development Group.
Senior Vice President, Human Resources and Corporate Services
Mr. Gillas is an industry veteran with more than 20 years of human resources experience in public companies. He most recently served as the Vice President of Compensation and Benefits at AMD, an international technology company. Prior to that, he spent 12 years at Hewlett-Packard, in a variety of roles, ending as Vice President and Managing Partner of Global Operations for Hewlett-Packard Technology Consulting. Mr. Gillas received his bachelor’s degree in Mathematics from Dickinson College.
Corporate Officer, Corporate Planning
Previously, Mr. Takashi Furukawa worked for the Bank of Japan, the Boston Consulting Group, and DDS Bioventure as CFO and Director. He then worked for Industrial Growth Platform, Inc. and provided services for corporate turnarounds and start-ups. Mr Furukawa graduated from the School of Chemical Engineering and received a Master’s degree in Economics from the University of Tokyo.
Corporate Officer, Management Administration
Previously, Mr. Kakutani was Executive Officer and General Manager of Finance Department of CareNet, Inc. (TSE, Mothers: 2150). Mr. Kakutani is a US Certified Public Accountant.